Insights
Search Results
Client Highlights
8.09.24
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Client Highlights
3.31.23
Firm Advises Cognito Therapeutics on $73 Million Series B Financing
On March 22, 2023, neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led by FoundersX Ventures with participation from all its existing investors. The round also included support from new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction.
Client Highlights
2.07.22
Wilson Sonsini Advises 1859, Inc. on Launch and $40 Million Series A
On February 7, 2022, 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale to discover new small molecule medicines for emerging disease targets, launched and announced the close of a $40 million Series A funding round led by Northpond Ventures and OMX Ventures. Existing investors FusionX Ventures and Vertical Venture Partners also joined the round. Wilson Sonsini Goodrich & Rosati advised 1859 on corporate and IP matters related to the company’s launch and financing.
Client Highlights
7.21.21
Wilson Sonsini Advises PacBio on Omniome Acquisition, Private Placement and Intended Collaboration Expansion with Invitae
On July 20, 2021, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy. Upon closing of the acquisition, PacBio will be uniquely positioned as the only company with both highly accurate long-read and short-read sequencing platforms. The company also announced two other transactions: a private placement for aggregate proceeds of approximately $300 million in connection with the proposed acquisition, and an intent to expand a multi-year collaboration with Invitae Corporation to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome.
White Papers/Briefs
3.03.21
Patent Protection in the FoodTech Space
The FoodTech industry is highly competitive and it can be challenging for companies to maintain a competitive edge. One way a FoodTech company can remain competitive is to seek patent protection for their innovations. This white paper provides a brief overview of the patenting process in the United States for FoodTech innovations, including what types of innovations can be patent protected and some hurdles to obtaining patent protection on natural products.
Client Highlights
3.03.21
Wilson Sonsini Represents WuXi AppTec in Acquisition of OXGENE
On March 2, 2021, WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has completed its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. Wilson Sonsini Goodrich & Rosati represented WuXi AppTec in the transaction, in collaboration with Taylor Wessing, which served as UK counsel.
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos